Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study.
Edward B GaronKatherine B WinfreeCliff MolifeZhanglin Lin CuiEdurne ArriolaBenjamin LevyTarek MekhailMaurice PérolPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2020)
In REVEL, the addition of ramucirumab to docetaxel did not increase HCRU among patients with aggressive aNSCLC disease. These results may help inform economic evaluation of treatment for patients with aNSCLC.